The global High-Content Screening market will have growth that is positive, with an overall valuation prediction of US$ 1.6 billion in 2022. With a predicted CAGR of 5.8%, the demand for high content screening is expected to soar.
High content screening (HCS) is crucial for drug discovery, disease research, and toxicity evaluation since it allows researchers to look at multiple cell properties at once. The demand for advanced screening techniques in the biotechnology and pharmaceutical industries is expected to propel the growth of the high content screening market.
HCS, also known as cellomics, has developed into a potent tool for drug discovery and biological research. It enables scientists to look at how different compounds affect cells and identify potential targets for more study. HCS systems store, analyze, and present data to give a comprehensive picture of biological responses using flow cytometry, digital microscopy, and sophisticated IT systems.
Master Complexity: Request Your Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-426
High content screening is used in the process of discovering and creating novel medications. The use of high content screening is expected to accelerate over the projected years due to growing research into target identification and validation, as well as the search for novel medication candidates. In addition, throughout the course of the projection period, demand is anticipated to increase due to a persistent focus on producing high-quality and technologically sophisticated cell imaging systems.
However, the COVID 19 epidemic severely hindered research and development efforts. This is expected to have a negative impact on the market. Nonetheless, increasing investments by key manufacturers in the development of advanced cell imaging product is expected to boost the market in the coming years.
Key Takeaways
- The CAGR for the global market over the preceding period was 5.1%.
- Over the coming decades, the market in India is anticipated to grow at a CAGR of 6.6%.
- With more than 7.3% of all demand recorded in Europe in 2022, Germany has emerged as a major market.
- Over the coming decade, the market in China is anticipated to grow at a CAGR of 7.8%.
- The highest demand for High Content Screenings came from the pharmaceutical and healthcare industries.
“The rising prevalence of multiple infectious diseases with a variety of symptoms raises the demand for innovative treatments. As a result, there will be an increase in biotechnology and pharmaceutical study and development efforts to identify new drug candidates. Imaging technologies are becoming increasingly important in drug discovery and analysis.” says an FMI analyst.
Competitive Landscape:
Key players in the HCS market employ strategies such as mergers and acquisitions, product launches, collaborations, and alliances to expand their businesses.
- Particle Works, a progressive company that creates and markets cutting-edge particle engineering platforms, declared the release of the Automated Library Synthesis (ALiS) System, a new ground-breaking platform, in November 2022. This innovative platform favors automation in the early stages of the creation of drugs as well as high-throughput evaluation of lipid nanoparticle (LNP) formulations and mRNA candidates.
- The Twist High Throughput Antibody Production platform, developed by California-based Twist Bioscience Corporation, was made public in April 2022. It allows customers to convert candidate genetic sequences into cleansed antibodies for use in a variety of applications related to screening and therapeutic discovery projects.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-426
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- Becton Dickinson, and Company
- GE Healthcare
- Olympus Corporation
- PerkinElmer Inc.
- Sysmex Corporation
- Merck KGaA
- Danaher Corporation
- Yokogawa Electric Corporation
- BioTek Instruments Inc.
Key Segments Profiled in the High Content Screening Industry Survey:
Product Type:
- Cell Imaging & Analysis
- HCS Instruments
- High-End HCS
- Mid End HCS
- Low-End HCS
- Flow Cytometers
- HCS Instruments
- Consumables
- Microplates
- Reagents & Assay Kits
- Other Consumables
- Software
- Services
Industry:
- Pharmaceutical & Healthcare
- Biotechnology
- Educational Institutions
- Independent CRO
- Government Organizations
- Others
Application:
- Primary & Secondary Screening
- Target Identification & Validation
- Toxicity Studies
- Compound Profiling
- Others
Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Get Full Market Analysis Now: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/426
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
